Antithrombotic Pharmacology Foundations
Core concept: Antithrombotic therapy targets platelets, the coagulation cascade, or fibrin itself. The correct agent depends on whether the clinical problem is platelet-rich arterial thrombosis, fibrin-rich venous or cardioembolic thrombosis, or an acute occlusive clot that requires reperfusion.
Key clinical distinction: Antiplatelet drugs, anticoagulants, and fibrinolytics are not interchangeable. Each changes a different part of thrombosis and carries a different monitoring and bleeding profile.
Prescribing priority: Define the indication, thrombotic risk, bleeding risk, kidney and liver function, interacting medications, pregnancy status, and need for procedures before selecting therapy. Document the monitoring plan and how major bleeding would be managed.
Start With the Thrombus You Are Trying to Prevent or Treat
Arterial thrombosis is usually platelet dominant, so antiplatelet therapy is central to acute coronary syndromes, coronary stents, chronic coronary disease, and most noncardioembolic ischemic stroke prevention. Venous thromboembolism and atrial-fibrillation-related embolism are more dependent on thrombin generation and fibrin, so anticoagulants are the primary drug class. Fibrinolytics break down fibrin-rich thrombi. They are reserved for time-sensitive, high-risk situations because bleeding, including intracranial hemorrhage, can be catastrophic (Huynh et al., 2026; Rogers & Spinler, 2026; Winkler, 2026).
Antiplatelet Therapy
Class | Examples | Primary effect | High-yield safety issue |
|---|---|---|---|
Cyclooxygenase inhibitor | Aspirin | Irreversibly suppresses platelet thromboxane A2 production | GI bleeding, hypersensitivity; dose and duration depend on indication |
P2Y12 inhibitors | Clopidogrel, prasugrel, ticagrelor | Reduce ADP-mediated platelet activation and aggregation | Bleeding; agent-specific contraindications and interactions; clopidogrel requires metabolic activation |
GP IIb/IIIa inhibitors | Eptifibatide, tirofiban | Block the final common pathway of platelet aggregation | Major bleeding and thrombocytopenia; usually limited to selected PCI settings |
Aspirin
Aspirin is foundational in many arterial-thrombotic syndromes because platelet cyclooxygenase inhibition is irreversible for the life of the platelet. Its role differs by context: acute loading in ACS or ischemic stroke, long-term single antiplatelet therapy in selected secondary-prevention settings, or combination therapy as part of dual antiplatelet therapy (DAPT). Bleeding risk rises when aspirin is combined with another antiplatelet, an anticoagulant, an NSAID, or heavy alcohol exposure (Rogers & Spinler, 2026; Winkler, 2026).
P2Y12 Inhibitors Are Not Interchangeable
Clopidogrel is a prodrug that requires CYP2C19 activation. Reduced-function alleles and drug interactions can decrease its antiplatelet effect. Prasugrel provides potent platelet inhibition but is contraindicated in patients with prior stroke or TIA and has greater bleeding concern in older or low-body-weight patients. Unlike clopidogrel, ticagrelor does not depend on CYP2C19 activation to the same extent. It requires twice-daily dosing and may cause bleeding or dyspnea. The prior stroke/TIA contraindication and age/weight precautions are specified in the prasugrel product labeling (Panacea Biotec Limited, 2025). Select the agent according to the ACS strategy, PCI status, bleeding risk, prior cerebrovascular disease, and adherence. Determine whether chronic oral anticoagulation is also needed (Rogers & Spinler, 2026). Cangrelor is the IV P2Y12 option used as an adjunct during PCI in selected patients who have not received an oral P2Y12 inhibitor; its very short effect requires deliberate transition to an oral agent (Rogers & Spinler, 2026).
Anticoagulant Classes
Class | Examples | Routine monitoring | Key prescribing distinction |
|---|---|---|---|
Unfractionated heparin (UFH) | IV or SC heparin | aPTT or anti-Xa when therapeutic; CBC/platelets | Rapid on/off; useful when renal function is poor or rapid reversibility is needed; highest HIT risk |
Low-molecular-weight heparin (LMWH) | Enoxaparin, dalteparin | Usually none; anti-Xa in selected patients | Predictable response; primarily renally cleared; lower HIT risk than UFH |
Indirect factor Xa inhibitor | Fondaparinux | No routine coagulation test | Renally cleared; avoid severe renal impairment; does not respond to protamine |
Direct factor Xa inhibitors | Apixaban, rivaroxaban, edoxaban | No routine INR/aPTT titration | Renal function, hepatic function, P-gp/CYP interactions, adherence, and indication-specific dosing matter |
Direct thrombin inhibitor | Dabigatran | No routine INR/aPTT titration | Substantial renal clearance; P-gp interactions; VTE treatment requires initial parenteral anticoagulation |
Vitamin K antagonist | Warfarin | PT/INR | Many drug/food interactions; slow onset; useful when DOACs are inappropriate, including mechanical valves |
Choose the Agent by the Patient, Not Just the Diagnosis
Kidney function often determines which anticoagulant is practical. UFH is often favored when severe renal impairment makes accumulation of LMWH, fondaparinux, or selected DOACs concerning. Use the renal criteria for the specific DOAC and indication. Kidney-function thresholds differ across drugs. Liver disease can also change exposure and bleeding risk. Reassess renal and hepatic function during long-term therapy because a dose that was appropriate six months ago may not remain appropriate (Huynh et al., 2026).
Pregnancy is another major boundary. LMWH is generally preferred for VTE treatment in pregnancy because it does not cross the placenta. Warfarin is teratogenic and is generally avoided during pregnancy except in highly specialized mechanical-valve situations. DOAC use during pregnancy is not established as a routine strategy (Huynh et al., 2026).
Warfarin Requires Deliberate Initiation and Follow-Up
Warfarin lowers vitamin-K-dependent clotting factors but also initially lowers natural anticoagulant proteins. When treating acute VTE, overlap warfarin with a rapidly acting parenteral anticoagulant for at least 5 days. Continue the overlap until the INR has been therapeutic for at least 24 to 48 hours. The usual VTE target INR is 2 to 3. Stable therapy still requires surveillance for diet changes, antibiotics, new prescriptions, OTC products, alcohol use, adherence, and bleeding (Huynh et al., 2026).
Heparin-Induced Thrombocytopenia Is a Prothrombotic Emergency
Suspect HIT when the platelet count falls substantially (often >50%), typically 5–10 days after heparin exposure, or when new thrombosis develops. Start with a 4Ts pretest-probability assessment. A low-probability 4Ts score generally argues against HIT testing or empiric heparin cessation solely for suspected HIT. With intermediate or high probability, stop all heparin products, including flushes, and obtain appropriate testing. Start nonheparin anticoagulation at an intensity based on thrombotic and bleeding risk. Do not switch UFH to LMWH when HIT is suspected (Huynh et al., 2026; Cuker et al., 2018).
Major Bleeding and Reversal
Antithrombotic | Reversal / major-bleeding approach | Clinical point |
|---|---|---|
UFH | Protamine sulfate | Rapidly neutralizes UFH; dose depends on recent heparin exposure |
LMWH | Protamine sulfate provides partial reversal | Protamine does not fully neutralize anti-Xa activity |
Warfarin | Rapid reversal with 4-factor PCC plus IV vitamin K when indicated; follow INR- and weight-based protocol. KCENTRA contains heparin and is contraindicated in known HIT and DIC; assess product-specific contraindications before administration. (CSL Behring, 2023). | Preferred over plasma for rapid reversal when available; reassess INR and thrombotic risk (Joglar et al., 2024). |
Dabigatran | Idarucizumab 5 g IV | Specific reversal; reassess need and timing to restart anticoagulation after hemostasis |
Apixaban / rivaroxaban | For life-threatening bleeding, rapid specialist-guided reversal and hemostatic support; 4-factor PCC may be used off-label according to institutional protocol. | Andexanet alfa (Andexxa) is no longer commercially available in the United States after December 22, 2025, following FDA safety concerns. Do not present it as a currently available U.S. reversal option (U.S. Food and Drug Administration, 2025). |
Care continues after anticoagulant reversal. After hemostasis, reassess why the patient bled, whether the anticoagulant dose was appropriate, whether kidney or liver function changed, and when thrombosis risk justifies restarting therapy. Failure to restart anticoagulation when the indication persists can expose the patient to stroke, PE, or recurrent VTE (Huynh et al., 2026).
Periprocedural and Neuraxial Safety
Interruption timing depends on the antithrombotic, kidney function, bleeding risk of the procedure, and urgency. Neuraxial procedures deserve special caution because spinal or epidural hematoma can cause permanent neurologic injury. Do not apply a single hold interval to every anticoagulant; use the current drug-specific and procedure-specific protocol (Huynh et al., 2026).
Fibrinolytics Remove Existing Clot
Fibrinolytics such as alteplase and tenecteplase activate plasminogen and promote fibrin clot breakdown. They are not maintenance antithrombotics and cannot replace antiplatelet or anticoagulant therapy. Eligibility, dose, timing, and post-treatment antithrombotic restrictions are indication specific: acute ischemic stroke, selected STEMI when timely PCI is unavailable, and selected high-risk PE use different protocols. Major bleeding, especially intracranial hemorrhage, is the defining safety concern. Use the indication-specific dose; stroke, STEMI, and PE protocols are not interchangeable (Huynh et al., 2026; Rogers & Spinler, 2026; Winkler, 2026).
High-Yield Distinctions
- Antiplatelet drugs are central to platelet-rich arterial thrombosis; anticoagulants are central to fibrin-rich venous and cardioembolic thrombosis.
- Fibrinolytics dissolve clot and carry substantially greater acute bleeding risk than routine antiplatelet or anticoagulant therapy.
- DOACs do not use routine INR titration, but they still require renal, hepatic, bleeding, interaction, and adherence surveillance.
- Apixaban and rivaroxaban can begin acute VTE treatment without parenteral lead-in; dabigatran and edoxaban require 5 to 10 days of initial parenteral anticoagulation.
- Mechanical heart valves and selected high-risk antiphospholipid syndrome are situations in which warfarin may remain preferred over a DOAC.
- A new platelet fall or thrombosis during heparin exposure should prompt a 4Ts assessment; stop all heparin and begin risk-appropriate nonheparin anticoagulation for intermediate/high-probability suspected HIT.
- Every antithrombotic prescription should include a plan for monitoring, procedure interruption, and major-bleeding management.
Related YourDNP Resources
- Arrhythmia Pharmacology Essentials
- Chronic Coronary Disease & Angina Pharmacotherapy
- Acute Coronary Syndromes Pharmacotherapy
- Venous Thromboembolism Pharmacotherapy
- Stroke & TIA Pharmacotherapy
Content last reviewed:
References
CSL Behring. (2023). KCENTRA (prothrombin complex concentrate [human]) [Prescribing information]. U.S. Food and Drug Administration. https://labeling.cslbehring.com/PI/US/Kcentra/EN/Kcentra-Prescribing-Information.pdf
Cuker, A., Arepally, G. M., Chong, B. H., Cines, D. B., Greinacher, A., Gruel, Y., Linkins, L.-A., Rodner, S. B., Selleng, S., Warkentin, T. E., Wex, A., Mustafa, R. A., Morgan, R. L., & Santesso, N. (2018). American Society of Hematology 2018 guidelines for management of venous thromboembolism: Heparin-induced thrombocytopenia. Blood Advances, 2(22), 3360–3392. https://doi.org/10.1182/bloodadvances.2018024489
Huynh, N. S., Cantrell, M., & Lee, J. C. (2026). Venous thromboembolism. In M. A. Chisholm-Burns, J. M. Kolesar, P. M. Malone, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., pp. 387-447). McGraw Hill.
Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., Gorenek, B., Hess, P. L., Hlatky, M., Hogan, G., Ibeh, C., Indik, J. H., Kido, K., Kusumoto, F., Link, M. S., . . . Van Wagoner, D. R. (2024). 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology, 83(1), 109–279. https://doi.org/10.1016/j.jacc.2023.08.017
Rogers, K. C., & Spinler, S. A. (2026). Acute coronary syndromes. In M. A. Chisholm-Burns, J. M. Kolesar, P. M. Malone, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., pp. 276-326). McGraw Hill.
U.S. Food and Drug Administration. (2025, December 18). Update on the safety of Andexxa by AstraZeneca: FDA safety communication. https://www.fda.gov/safety/medical-product-safety-information/update-safety-andexxa-astrazeneca-fda-safety-communication
Winkler, S. R. (2026). Stroke. In M. A. Chisholm-Burns, J. M. Kolesar, P. M. Malone, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., pp. 448-477). McGraw Hill.